Search
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAlthough initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. … Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.
Products: TRACTOCILE 7.5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION, TRACTOCILE (7.5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION)Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalEravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727]. … It was first approved by the FDA on August 27, 2018 [L4540].
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIALOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease. … [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]
Products: XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONAlemtuzumab
go.drugbank.com/drugs/DB00087ApprovedInvestigational[L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). … The dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing.[L43397, L30335]
Products: LEMTRADA Concentrate for Solution for Infusion 12 mg, LEMTRADA CONCENTRATE FOR SOLUTION FOR INFUSION 12 MG/ 1.2 MLVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or
Products: Entyvio 300mg Powder for Concentrate for Solution for Infusion, ENTYVIO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 300MG/VIALEnfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigationalThe clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December … [L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000]
Products: Padcev 30mg Powder for Concentrate for Solution for Infusion, Padcev 20mg Powder for Concentrate for Solution for InfusionNatalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalIn 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy
Products: Tysabri Concentrate for Solution for Infusion 300mg/15mlInsulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigationalInsulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. … [A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETProducts: Tresiba® FlexTouch® 100 U/ml Solution for Injection, Tresiba ® FlexTouch® 100 U/ml Solution for InjectionCefoxitin
go.drugbank.com/drugs/DB01331ApprovedInvestigationalCefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Cefoxitin for Injection, Cefoxitin for Injection USPCromoglicic acid
go.drugbank.com/drugs/DB01003ApprovedInvestigationalA chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. … It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.
Categories: Drugs for Obstructive Airway Diseases, Agents for Dermatitis, Excluding CorticosteroidsProducts: CROMO-STULLN UD, CROMOHEXAL UD EDP